Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8208036 | 0.95 | EDNRA (0.78) | EDNRAEDNRB | |
| SCHEMBL7532849 | 0.95 | EDNRA (0.83) | EDNRAEDNRB | |
| SCHEMBL7809560 | 0.93 | EDNRA (0.81) | EDNRAEDNRB | |
| SCHEMBL7538653 | 0.93 | EDNRA (0.79) | EDNRAEDNRB | |
| SCHEMBL8202830 | 0.91 | EDNRA (0.77) | EDNRAEDNRB | |
| SCHEMBL8203958 | 0.91 | EDNRA (0.82) | EDNRAEDNRB | |
| SCHEMBL6962257 | 0.90 | EDNRA (0.75) | EDNRAEDNRB | |
| Enrasentan SCHEMBL1649828 | 0.89 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL7636324 | 0.89 | EDNRA (1.00) | EDNRAEDNRB | |
| Enrasentan SCHEMBL8206689 | 0.89 | EDNRA (1.00) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.